Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franco Muggia

Showing results (71-80 of 95) with videos related to

Pageof 10
Sort By:
Cancer Investigation|March 20, 2003
A phase II study of 13-cis retinoic acid plus interferon alpha-2a in advanced stage penile carcinoma: an Eastern Cooperative Oncology Group study (E3893)Roland T Skeel, Jie Huang, Judith Manola, et al.
Anticancer Research|December 27, 2011
Loss of p27KIP1 expression in fully-staged node-negative breast cancer: association with lack of hormone receptors in T1a/b, but not T1c infiltrative ductal carcinomaDeepu Mirchandani, Daniel F Roses, Giorgio Inghirami, et al.
Gynecologic Oncology|June 16, 2010
A phase I trial of dose-dense (biweekly) carboplatin combined with paclitaxel and pegfilgrastim: a feasibility study in patients with untreated Stage III and IV ovarian, tubal or primary peritoneal cancer: a Gynecologic Oncology Group studyAmy D Tiersten, Michael W Sill, Danielle Knight, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 21, 2007
Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group StudyWilliam E Winter, G Larry Maxwell, Chunqiao Tian, et al.
The Oncologist|May 25, 2012
Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences?Maryann Kwa, Robert Baumgartner, Linda Shavit, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2004
Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumorsSridhar Mani, Hayley McDaid, Anne Hamilton, et al.
Anticancer Research|April 12, 2012
A pilot study of letrozole for one year in women at enhanced risk of developing breast cancer: effects on mammographic densityJulia Smith, Asma Dilawari, Giske Ursin, et al.
Gynecologic Oncology|December 10, 2016
Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancerFernanda Musa, Bhavana Pothuri, Stephanie V Blank, et al.
Gynecologic Oncology|September 10, 2011
The regulation of MASPIN expression in epithelial ovarian cancer: association with p53 status, and MASPIN promoter methylation: a gynecologic oncology group studyAngeles Alvarez Secord, Kathleen M Darcy, Alan Hutson, et al.
Gynecologic Oncology|June 26, 2021
Breast cancer incidence in BRCA mutation carriers with ovarian cancer: A longitudal observational studyTamar Safra, Barliz Waissengrin, Deanna Gerber, et al.
Pageof 10

Showing results (71-80 of 95) with videos related to

Sort By:
Pageof 10
Cancer Investigation|March 20, 2003
A phase II study of 13-cis retinoic acid plus interferon alpha-2a in advanced stage penile carcinoma: an Eastern Cooperative Oncology Group study (E3893)Roland T Skeel, Jie Huang, Judith Manola, et al.
Anticancer Research|December 27, 2011
Loss of p27KIP1 expression in fully-staged node-negative breast cancer: association with lack of hormone receptors in T1a/b, but not T1c infiltrative ductal carcinomaDeepu Mirchandani, Daniel F Roses, Giorgio Inghirami, et al.
Gynecologic Oncology|June 16, 2010
A phase I trial of dose-dense (biweekly) carboplatin combined with paclitaxel and pegfilgrastim: a feasibility study in patients with untreated Stage III and IV ovarian, tubal or primary peritoneal cancer: a Gynecologic Oncology Group studyAmy D Tiersten, Michael W Sill, Danielle Knight, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 21, 2007
Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group StudyWilliam E Winter, G Larry Maxwell, Chunqiao Tian, et al.
The Oncologist|May 25, 2012
Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences?Maryann Kwa, Robert Baumgartner, Linda Shavit, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2004
Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumorsSridhar Mani, Hayley McDaid, Anne Hamilton, et al.
Anticancer Research|April 12, 2012
A pilot study of letrozole for one year in women at enhanced risk of developing breast cancer: effects on mammographic densityJulia Smith, Asma Dilawari, Giske Ursin, et al.
Gynecologic Oncology|December 10, 2016
Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancerFernanda Musa, Bhavana Pothuri, Stephanie V Blank, et al.
Gynecologic Oncology|September 10, 2011
The regulation of MASPIN expression in epithelial ovarian cancer: association with p53 status, and MASPIN promoter methylation: a gynecologic oncology group studyAngeles Alvarez Secord, Kathleen M Darcy, Alan Hutson, et al.
Gynecologic Oncology|June 26, 2021
Breast cancer incidence in BRCA mutation carriers with ovarian cancer: A longitudal observational studyTamar Safra, Barliz Waissengrin, Deanna Gerber, et al.
Pageof 10